We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi
Dr Bonnie 360 interviews Chase Spurlock, PhD, founder and CEO of Decode Health on AI analytics in COVID and chronic inflammatory disease.
In Part 2 of The State of Autoimmunity 2016, we will examine how established and emerging companies are utilizing advances in technology. More importantly, we describe how these companies and chronic disease management platforms can help create individualized autoimmune care. In Part 1, we discussed autoimmune disease as an untapped
On GI practice, beta risk, digital health, VBP and chronic care Another in our new series of B2B thought leadership interviews with visionary entrepreneurs applying digital tools to improve care of chronic immunoinflammatory disorders (CID), including autoimmune and autoinflammatory diseases. We were delighted to speak with Dr Lawrence R. Kosinski,
See Part 1 for how Bonnie met Bill Conlan pre-CrossBridge and for background on his entrepreneurial track record. That background includes SaaS platforms, analytics and the migration from fee-for-service (FFS) to value-based payments (VBP). Part 1 also lays out the challenges Bill saw for specialty practices in chronic disease management.
Welcome to our B2B Thought Leadership series! We are delighted to start with a 2-part post from our interview with Bill Conlan, founder and CEO of CrossBridge. CrossBridge is a Software as a Service (SaaS) platform using data analytics to bridge care coordination gaps between healthcare payers and specialty provider
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi
Dr Bonnie 360 interviews Chase Spurlock, PhD, founder and CEO of Decode Health on AI analytics in COVID and chronic inflammatory disease.
In Part 2 of The State of Autoimmunity 2016, we will examine how established and emerging companies are utilizing advances in technology. More importantly, we describe how these companies and chronic disease management platforms can help create individualized autoimmune care. In Part 1, we discussed autoimmune disease as an untapped
On GI practice, beta risk, digital health, VBP and chronic care Another in our new series of B2B thought leadership interviews with visionary entrepreneurs applying digital tools to improve care of chronic immunoinflammatory disorders (CID), including autoimmune and autoinflammatory diseases. We were delighted to speak with Dr Lawrence R. Kosinski,
See Part 1 for how Bonnie met Bill Conlan pre-CrossBridge and for background on his entrepreneurial track record. That background includes SaaS platforms, analytics and the migration from fee-for-service (FFS) to value-based payments (VBP). Part 1 also lays out the challenges Bill saw for specialty practices in chronic disease management.
Welcome to our B2B Thought Leadership series! We are delighted to start with a 2-part post from our interview with Bill Conlan, founder and CEO of CrossBridge. CrossBridge is a Software as a Service (SaaS) platform using data analytics to bridge care coordination gaps between healthcare payers and specialty provider